Bio Path Holdings Inc

NASDAQ:BPTHUnited States

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company. It utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein. Its modified product named prexigebersen-A, is its fourth drug candidate.

Contact Information

Headquarters

4710 Bellaire Blvd Ste 210BELLAIRE, TX, United States 77401-4505

Phone

832-742-1357

Fax

916-443-1908

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Treasurer

Peter Nielsen

Director of Investor Relations, Secretary, Director

Douglas Morris

Independent Director

Paul Aubert

Independent Director

Heath Cleaver

Independent Director

Aline Sherwood